Soins de santé

The Opportunity for Walgreens in The World of Clinical Trials

sept. 25, 2024

Guest: Ramita Tandon, Chief Clinical Trials Officer, Walgreens

Host: Charles Rhyee, Health Care Analyst, TD Cowen

Walgreens launched its Clinical Trials business in 2022 to make clinical trials more accessible, convenient and equitable for the nearly 80% of Americans who live near a Walgreens store. Since then, the company has seen solid growth in this business and now working with more than 25 biopharmaceutical companies, academic institutions, nonprofits and government entities.

Clinical research organizations (CROs) and manufacturers are highly interested in working with a partner like Walgreens that can address patient convenience, study recruitment efficiency and trial participant diversity. Walgreens is also able to scale this business in a capital light approach leveraging its existing retail pharmacy network. To discuss this topic, we're joined by Ramita Tandon, Walgreen's Chief Clinical Trials Officer.

This podcast was originally recorded on September 10, 2024.

Full transcript to come.

Disclaimer

This podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this recording was obtained from publicly available sources, has not been independently verified by TD Securities, may not be current, and TD Securities has no obligation to provide any updates or changes. All price references and market forecasts are as of the date of recording. The views and opinions expressed in this podcast are not necessarily those of TD Securities and may differ from the views and opinions of other departments or divisions of TD Securities and its affiliates. TD Securities is not providing any financial, economic, legal, accounting, or tax advice or recommendations in this podcast. The information contained in this podcast does not constitute investment advice or an offer to buy or sell securities or any other product and should not be relied upon to evaluate any potential transaction. Neither TD Securities nor any of its affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefore (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed.

Charles Rhyee

Directeur général, Soins de santé – Analyste de recherche en technologies de soins de santé, TD Cowen

Charles Rhyee
Directeur général, Soins de santé – Analyste de recherche en technologies de soins de santé, TD Cowen

Biographie

Charles Rhyee est directeur général et analyste de recherche principal en distribution et technologies de soins de santé. M. Rhyee a été reconnu dans les sondages menés par le Wall Street Journal et le Financial Times. En 2023, il s’est classé au troisième rang du sondage All-America dans le segment de la distribution et des technologies de soins de santé du magazine Institutional Investor et a été nommé Best Up & Coming Analyst en 2008 et en 2009.

Avant de se joindre à TD Cowen en février 2011, il a occupé le poste de directeur général de la distribution et des technologies de soins de santé pour Oppenheimer & Co. M. Rhyee a commencé sa carrière en recherche sur les actions à Salomon Smith Barney en 1999.

Il est titulaire d’un baccalauréat en économie de l’Université Columbia.